Jacobus Pfisterer

Jacobus Pfisterer

UNVERIFIED PROFILE

Are you Jacobus Pfisterer?   Register this Author

Register author
Jacobus Pfisterer

Jacobus Pfisterer

Publications by authors named "Jacobus Pfisterer"

Are you Jacobus Pfisterer?   Register this Author

77Publications

1862Reads

10Profile Views

Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.

Gynecol Oncol 2019 Jun 21;153(3):616-624. Epub 2019 Mar 21.

Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Kiel, Germany; Onkologisches Therapiezentrum, Krankenhaus Jerusalem, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.015DOI Listing
June 2019

Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:342-350. Epub 2019 May 17.

1 University of Virginia, Charlottesville, VA.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/EDBK_237945
Publisher Site
http://dx.doi.org/10.1200/EDBK_237945DOI Listing
January 2019

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Int J Gynecol Pathol 2018 Jul 27. Epub 2018 Jul 27.

British Columbia Cancer Agency (J.M., A.N.K., A.T., D.C., D.G.H.) Department of Pathology, University of British Columbia (A.N.K., B.T.-C., C.C., A.C., C.B.G., D.G.H.), Vancouver, British Columbia, Canada Memorial Sloan Kettering Cancer Center, New York, New York (R.S.) Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (S.H.) Department of Women's Health, Tübingen University Hospital, Tübingen (S.K.) Department of Gynecologic Oncology, Kliniken Essen Mitte, Essen (A.D.B.) Gynecologic Oncology Center, Kiel (J.P.) Institute of Pathology, Friedrichshafen (F.K.), Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000538DOI Listing
July 2018

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Gynecol Oncol 2016 Mar 28;140(3):450-6. Epub 2015 Dec 28.

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe, Arnold-Heller-Str. 3, Haus 24, 24105 Kiel, Germany,. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.12.025DOI Listing
March 2016

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.

Gynecol Oncol 2016 Mar 22;140(3):457-62. Epub 2016 Jan 22.

Department of Gynecology and Gynecological Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.01.022DOI Listing
March 2016

Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Am J Surg Pathol 2015 Nov;39(11):1548-57

*Department of Molecular Oncology §Cancer Control Research, BC Cancer Agency Cancer Research Centre †Department of Pathology and Laboratory Medicine ‡Genetic Pathology Evaluation Centre, Anatomical Pathology at the Vancouver General Hospital ‡‡Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, BC, Canada ∥Department of Internal Medicine, University of New Mexico, Albuquerque, NM §§Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB ¶The Leeds Teaching Hospitals NHS Trust, Leeds #Barts Health NHS Trust, London, United Kingdom **Institut für Pathologie, Referenzzentrum für Gynäkopathologie, Mannheim ††Gynecologic Oncology Center, Kiel ∥∥Department of Gynecology and Obstetrics, Tuebingen University Women's Hospital, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604016PMC
November 2015

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.

Int J Gynecol Cancer 2015 Sep;25(7):1248-52

*Department of Gynecology Charité, Campus Virchow Klinikum, Berlin, Germany; †Imperial College London, London, United Kingdom; ‡Gynäkologie & Gynäkologische Onkologie, Dr. Horst Schmidt Klinik, Wiesbaden; §Frauenklinik Universitätsklinikum Ulm, Ulm; ∥Coordinating Center for Clinical Trials, University Marburg, Marburg; ¶Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg; #Referenzzentrum für Gynäkopathologie, Institut für Pathologie, Mannheim; **Frauen- und Poliklinik, Klinikum der Technischen Universität, Muenchen; ††Frauenklinik Universitätsklinikum Tuebingen, Tuebingen; ‡‡Frauenheilkunde und Geburtshilfe, Klinikum der J.W. Goethe-Universität, Frankfurt; §§Klinik für Frauenheilkunde und Geburtshilfe der Universität Duisburg-Essen, Essen; ∥∥Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Technische Universität Dresden, Dresden; ¶¶Zentrum für Gynäkologische Onkologie, Kiel; ##Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen; ***Universitätsklinik und Poliklinik für Gynäkologie, Universitätsklinikum, Halle; and †††Gynäkologie & Gynäkologische Onkologie, Kliniken Essen-Mitte, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000476DOI Listing
September 2015

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Mol Cancer Ther 2015 Jun 7;14(6):1495-503. Epub 2015 Apr 7.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0039DOI Listing
June 2015

Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S109-16

*Department of Gynecology and Obstetrics, IRCCS San Raffaele Hospital, Milan, Italy; †Gynecologic Oncology Department, Catholic University of the Sacred Heart, Rome/Campobasso, Italy; ‡Gynecologic Oncology Group, The University of Texas MD Anderson Cancer Center, Houston, TX; §AGO Study Group, Gynecologic Oncology Center, Kiel, Germany; ∥Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ¶ANZGOG, Camperdown, New South Wales, Australia; #Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, Hong Kong, People's Republic of China; **Centre de Référence des Maladie Trophoblastiques, Hospices Civils de Lyon, Lyon, France; ††Department of Obstetrics and Gynecology, Institute of Maternal and Child Health, Medical College, Calicut, India; ‡‡GTD unit, University Hospital of Caracas, Central University of Venezuela, Caracas, Venezuela; §§The Spanish Ovarian Cancer Research Group (GEICO), Fundación Instituto Valenciano de Oncología, Valencia, Spain; ∥∥Korean Gynaecologic Oncology Group, Seoul National University Hospital, Seoul, South Korea; ¶¶Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; ##Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and ***Charing Cross Trophoblastic Disease Centre, Departments of Histopathology and Medical Oncology, Charing Cross Campus of Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000294DOI Listing
November 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S14-9

*UCL Cancer Institute and UCL Hospitals, London UK; †Hartford Hospital, Hartford, CT; ‡University of Louisville School of Medicine, Louisville, KY; §IRCCS San Raffaele Hospital, Milan, Italy; ∥The Prince of Wales Hospital Randwick, New South Wales, Australia; ¶Gynecologic Oncology Center, Kiel, Germany; #Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; **Seoul National University College of Medicine, Seoul, Korea; ††Paris Descartes University, Cochin-Hôtel Dieu, Paris; ‡‡Princess Margaret Hospital, Toronto, Canada; and §§MD Anderson Cancer Centre, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000296DOI Listing
November 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S20-5

*Jikei University School of Medicine, Tokyo, Japan; †Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; ‡Osaka University Graduate School of Medicine, Osaka, Japan; §Kyoto University Graduate School of Medicine, Kyoto, Japan; ∥Keio University, Tokyo, Japan; ¶Tottori University School of Medicine, Tottori, Japan; #National Defense Medical College, Saitama, Japan; **Clinical Research, Innovation, and Education Center, Tohoku University Hospital, Sendai, Japan; ††Sunnybrook Hospital, Toronto, Canada; ‡‡UCL Cancer Institute, London, United Kingdom; §§Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ∥∥Border Medical Oncology, Victoria, Australia; ¶¶Department of Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom; ##Institute of Cancer Sciences, University of Glasgow Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom; ***Gynecologic Oncology Center, Kiel, Germany; †††National Cancer Center, Goyang, Korea; ‡‡‡Institut Claudius Regaud, Toulouse, France; §§§National Cancer Institute, Naples, Italy; and ∥∥∥Princess Margaret Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000289DOI Listing
November 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S5-8

*Kliniken-Essen-Mitte, AGO, Essen, Germany; †MD Andersen Cancer Center, GOG, Houston, TX; ‡Gustave Roussy, GINECO, Villejuif Cedex, France; §Université René Descartes, GINECO, Paris, France; ∥UCL Cancer Institute, MRC NCRI, London, United Kingdom; ¶CHUM-Notre-Dame Hospital, NCIC-CTG, Montreal, Quebec, Canada; #Fondazione IRCCS Istituto Nazionale dei Tumori, MITO, Milan, Italy; **ANZGOG, Parkville, Victoria, Australia; ††University and University Hospital of Tampere, NSGO, Tampere, Finland; ‡‡Seoul National University, KGOG, Seoul, South Korea; §§University Medical Center Hamburg-Eppendorf, AGO, Hamburg, Germany; ∥∥University Hospital Kiel, AGO, Kiel, Germany; ¶¶UKGM, Marburg, AGO, Marburg, Germany; and ##Gynecologic Oncology Center, Kiel, AGO, Kiel, Germany.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ijgc/2014/11003/Gynecologic_Can
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000282DOI Listing
November 2014

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.

Histopathology 2013 Nov 2;63(5):704-12. Epub 2013 Sep 2.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Gynecology and Obstetrics, Tuebingen University, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12219DOI Listing
November 2013

Specialized pathology review in patients with ovarian cancer: results from a prospective study.

Int J Gynecol Cancer 2013 Oct;23(8):1376-82

*Universitäts-Frauenklinik Tübingen, Germany; †AGO Study Group, Wiesbaden, Germany; §Philipps-Universität Marburg, Koordinierungszentrum für klinische Studien, Marburg, Germany; ∥Luzerner Kantonsspital, Institute of Pathology, Luzern, Switzerland; ¶Institute of Pathology, Dueren, Germany; #Horst-Schmidt-Kliniken (HSK), Wiesbaden, Germany; ††Institute of Pathology, Mannheim, Germany; ‡Gynecologic Oncology Center, Kiel, Germany; and **Department Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ijgc/2013/10000/Specialized_Pat
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0b013e3182a01813DOI Listing
October 2013

Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.

Gynecol Oncol 2013 Jun 15;129(3):463-6. Epub 2013 Mar 15.

Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Department of Gynecology and Gynecologic Oncology, Henricistrasse 92, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.03.007DOI Listing
June 2013

Towards individualised treatment in ovarian cancer.

Lancet Oncol 2013 Feb;14(2):101-2

University Medical Center Hamburg-Eppendorf, Department of Gynecology and Gynecologic Oncology, Martinistrasse 52, 20246 Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70006-8DOI Listing
February 2013

Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience.

Onkologie 2012 24;35(3):76-81. Epub 2012 Feb 24.

Klinik für Gynäkologie und Geburtshilfe, UKSH Campus Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000336829DOI Listing
September 2012

Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.

Support Care Cancer 2011 Sep 6;19(9):1421-7. Epub 2010 Aug 6.

Department of Obstetrics and Gynecology, Medical University Graz, Auenbruggerplatz 14, 8036, Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-010-0969-8DOI Listing
September 2011

Surgery for recurrent ovarian cancer.

Womens Health (Lond) 2011 Sep;7(5):529-35

Department of Gynecology & Gynecological Oncology, Kliniken Essen-Mitte, Huyssen-Stiftung/Knappschaft GmbH, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/whe.11.52DOI Listing
September 2011

Abagovomab for ovarian cancer.

Expert Opin Biol Ther 2011 Mar 18;11(3):395-403. Epub 2011 Jan 18.

Klinik für Gyäkologie und Geburtshilfe Städtisches Klinikum Solingen, Gotenstr. 1, 42653 Solingen, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14712598.2011.55
Publisher Site
http://dx.doi.org/10.1517/14712598.2011.553598DOI Listing
March 2011

Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Immunotherapy 2011 Feb;3(2):153-62

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.10.100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221001PMC
February 2011

Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials.

J Clin Oncol 2010 Apr 1;28(10):1733-9. Epub 2010 Mar 1.

Departments of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig-Erhard-Str 100, D-65199 Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.25.3617
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.25.3617DOI Listing
April 2010

Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.

Hum Immunol 2010 Jan;71(1):36-44

Klinik für Gynäkologie, Gyn. Endokrinologie und Onkologie, Universitätsklinikum, Giessen und Marburg, GmbH, 35043 Marburg, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S019888590900580
Publisher Site
http://dx.doi.org/10.1016/j.humimm.2009.09.356DOI Listing
January 2010

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Expert Rev Anticancer Ther 2010 Jan;10(1):81-8

Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig-Erhard-Strasse 100, D-65199 Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.165DOI Listing
January 2010

Prognostic factors for complete debulking in first- and second-line ovarian cancer.

Int J Gynecol Cancer 2009 Dec;19 Suppl 2:S14-7

Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig-Erhard Strasse 100,Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181bffb3fDOI Listing
December 2009

Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review.

Gynecol Oncol 2009 Feb 6;112(2):422-36. Epub 2008 Nov 6.

Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Klinik (HSK), Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009082580800810
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2008.09.036DOI Listing
February 2009

Management of platinum-sensitive recurrent ovarian cancer.

Semin Oncol 2006 Apr;33(2 Suppl 6):S12-6

Klinik für Gynäkologie und Geburtshilfe Campus Kiel, Universitätsklinikum Schleswig-Holstein, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.03.012DOI Listing
April 2006

The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.

Gynecol Oncol 2004 Oct;95(1):89-94

Department of Obstetrics and Gynecology, University of Freiburg Medical School, Freiburg D-79098, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.06.048DOI Listing
October 2004

[Therapy of advanced ovarian carcinoma].

Krankenpfl J 2004 ;42(1-2):18-9

Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel.

View Article

Download full-text PDF

Source
September 2004

Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapy.

Anticancer Res 2004 Mar-Apr;24(2B):929-34

Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Germany.

View Article

Download full-text PDF

Source
July 2004

A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.

Auris Nasus Larynx 2004 Jun;31(2):149-53

Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Arnold-Heller-Strasse 14, D-24105 Kiel, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S038581460400005
Publisher Site
http://dx.doi.org/10.1016/j.anl.2004.01.007DOI Listing
June 2004

Docetaxel-induced nail changes--a neurogenic mechanism: a case report.

J Neurooncol 2002 Jun;58(2):167-74

Klinik für Neurologie, Universitätsklinikum der Christian-Albrechts-Universität zu Kiel, Germany.

View Article

Download full-text PDF

Source
June 2002